{"title":"葱乙酸乙酯提取物辅助治疗COVID-19的疗效和安全性：一项随机、多中心、对照临床试验","authors":"Mansour Amin, Mandana Pouladzadeh, Mohammad Jaafar Yadyad, Roshanak Roshanfard, Mohamad Hasan Pipelzadeh, Afshin Talebi, Behzad Sharif Maakhmalzadeh, Mehdi Bijanzadeh, Nasrin Rakipour, Gholamreza Alizadehattar, Seyed Saeed Seyedian, Kambiz Ahmadi Angali, Parastoo Moradi Choghakabodi, Akbar Akbari, Fatemeh Maghsodi, Ebrahim Barzegari, Maryam Jamalan, Reza Aalizadeh, Mostafa Jamalan","doi":"10.22038/AJP.2024.24523","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Given the apparent life-threatening nature of COVID-19, finding an effective treatment is under investigation.</p><p><strong>Materials and methods: </strong>We assessed effect of shallomin oral syrup (co IranAmin<sup>®</sup>) as a complementary treatment to improve the clinical outcomes in COVID-19 patients. Patients in the control group received the approved treatment protocol (lopinavir/ritonavir), while those in the intervention group were treated with the oral syrup shallomin in addition to the approved treatment. Clinical status of treated patients was recorded and compared.</p><p><strong>Results: </strong>There were meaningful differences between the two groups regarding shortened length of hospital stay and the recovery time for cough, myalgia, sore throat, and shortness of breath. No side effect occurred in the intervention group compared to the control group in terms of biochemical and hematological factors.</p><p><strong>Conclusion: </strong>It seems that the treatment with shallomin syrup showed remarkable contribution to the recovery of COVID-19 induced symptoms in the patients under lopinavir/ritonavir therapy.</p>","PeriodicalId":8677,"journal":{"name":"Avicenna Journal of Phytomedicine","volume":"14 6","pages":"699-710"},"PeriodicalIF":1.9000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12009622/pdf/","citationCount":"0","resultStr":"{\"title\":\"Examining efficacy and safety of ethyl acetate extract from <i>Allium hirtifolium</i> as complementary therapy in COVID-19: A randomized, multicenter, controlled clinical trial.\",\"authors\":\"Mansour Amin, Mandana Pouladzadeh, Mohammad Jaafar Yadyad, Roshanak Roshanfard, Mohamad Hasan Pipelzadeh, Afshin Talebi, Behzad Sharif Maakhmalzadeh, Mehdi Bijanzadeh, Nasrin Rakipour, Gholamreza Alizadehattar, Seyed Saeed Seyedian, Kambiz Ahmadi Angali, Parastoo Moradi Choghakabodi, Akbar Akbari, Fatemeh Maghsodi, Ebrahim Barzegari, Maryam Jamalan, Reza Aalizadeh, Mostafa Jamalan\",\"doi\":\"10.22038/AJP.2024.24523\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Given the apparent life-threatening nature of COVID-19, finding an effective treatment is under investigation.</p><p><strong>Materials and methods: </strong>We assessed effect of shallomin oral syrup (co IranAmin<sup>®</sup>) as a complementary treatment to improve the clinical outcomes in COVID-19 patients. Patients in the control group received the approved treatment protocol (lopinavir/ritonavir), while those in the intervention group were treated with the oral syrup shallomin in addition to the approved treatment. Clinical status of treated patients was recorded and compared.</p><p><strong>Results: </strong>There were meaningful differences between the two groups regarding shortened length of hospital stay and the recovery time for cough, myalgia, sore throat, and shortness of breath. No side effect occurred in the intervention group compared to the control group in terms of biochemical and hematological factors.</p><p><strong>Conclusion: </strong>It seems that the treatment with shallomin syrup showed remarkable contribution to the recovery of COVID-19 induced symptoms in the patients under lopinavir/ritonavir therapy.</p>\",\"PeriodicalId\":8677,\"journal\":{\"name\":\"Avicenna Journal of Phytomedicine\",\"volume\":\"14 6\",\"pages\":\"699-710\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12009622/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Avicenna Journal of Phytomedicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22038/AJP.2024.24523\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Avicenna Journal of Phytomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22038/AJP.2024.24523","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Examining efficacy and safety of ethyl acetate extract from Allium hirtifolium as complementary therapy in COVID-19: A randomized, multicenter, controlled clinical trial.
Objective: Given the apparent life-threatening nature of COVID-19, finding an effective treatment is under investigation.
Materials and methods: We assessed effect of shallomin oral syrup (co IranAmin®) as a complementary treatment to improve the clinical outcomes in COVID-19 patients. Patients in the control group received the approved treatment protocol (lopinavir/ritonavir), while those in the intervention group were treated with the oral syrup shallomin in addition to the approved treatment. Clinical status of treated patients was recorded and compared.
Results: There were meaningful differences between the two groups regarding shortened length of hospital stay and the recovery time for cough, myalgia, sore throat, and shortness of breath. No side effect occurred in the intervention group compared to the control group in terms of biochemical and hematological factors.
Conclusion: It seems that the treatment with shallomin syrup showed remarkable contribution to the recovery of COVID-19 induced symptoms in the patients under lopinavir/ritonavir therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
